HLA-DRB1等位基因多态性与肝癌发病风险关系的系统评价

Association between HLA-DRB1 alleles polymorphism and hepatocellular carcinoma：a systematic review

摘要:

目的：系统评价HLA-DRB1*07/12/15与肝癌[本文的肝癌指的是肝细胞癌（hepatocellular carcinoma，HCC）]的发病风险关系。方法：计算机检索PubMed、EMBASＥ、万方数据库、中国知网全文数据库（CNKI），纳入HLA-DRB1*07/12/15与HCC发病风险关系的病例对照研究，对纳入的研究提取有效数据，采用统计软件RevMan 5.0进行Meta分析，效应指标采用OR值表示。结果：HLA-DRB1*12/15增加了整个人群HCC的发病风险[（OR=1.56，95%CI＝1.12～2.17，P=0.009）/（OR=1.35，95%CI＝1.03～1.77，P=0.03）]，HLA-DRB1*07与整个人群HCC的发病无明显关系（OR=0.99，95%CI＝0.46～2.14，P=0.97）；亚组分析结果提示：HLA-DRB1*12/15增加了亚洲人群HCC的发病风险[（OR=1.65，95%CI＝1.17～2.32，P=0.004）/（OR=1.55，95%CI＝1.14～2.11，P=0.006）]，HLA-DRB1*07与亚洲人群HCC的发病风险无明显关系（OR=0.95，95%CI＝0.26～3.50，P=0.94）。结论：HLA-DRB1*12/15增加了HCC的发病风险，HLA-DRB1*07与HCC的发病无明显关系。

Abstract:

Objective：To investigate the correlation between HLA-DRB1*07/12/15 and hepatocellular carcinoma（HCC）. Methods：Articles were identified by electronic search in PubMed，EMBASE，Wanfang data，CNKI. Case-control study trials focusing on the correlation of the risk of HLA-DRB1*07/12/15 with HCC were included. Effective data were extracted from the eligible studies. All Meta analysis were performed by RevMan 5.0 software. ORs were used as effect indicators. Results：HLA-DRB1*12/15 increased the risk of HCC in the whole populations[（OR=1.56，95%CI=1.12 to 2.17，P=0.009）/（OR=1.35，95%CI=1.03 to 1.77，P=0.03）] while HLA-DRB1*07 didn’t correlated with the risk of HCC in the whole populations（OR=0.99，95%CI=0.46 to 2.14，P=0.97）. Subgroup analyzis suggested that：HLA-DRB1*12/15 increased the risk of HCC in Asian populations[（OR=1.65，95%CI=1.17 to 2.32，P=0.004）/（OR=1.55，95%CI=1.14 to 2.11，P=0.006）]，while HLA-DRB1*07 didn’t correlated with the risk of HCC in Asian populations significantly（OR=0.95，95%CI=0.26 to 3.50，P=0.94）. Conclusion：HLA-DRB1*12/15 increases the risk of HCC while HLA-DRB1*07 doesn’t correlate with the risk of HCC.